SCHEMBL16379014

SCHEMBL16379014

CNc1cccc(C2CCCCC2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.49
HDAC4 P56524 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
XBP1 P17861 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDO2 P48775 1/20 0.43
CYP11B2 P19099 1/20 0.42
TRIM24 O15164 2/20 0.41
HTR2C P28335 2/20 0.40
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC18A3 Q16572 1/20 0.39
CTSK P43235 1/20 0.38
PRKCI P41743 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27990535 0.96 HDAC4 (0.46) KMOHDAC4HDAC2HDAC8LMNA
SCHEMBL21917550 0.95 KMO (0.47) KMOHDAC4HDAC2HDAC8LMNA
SCHEMBL22104134 0.94 HDAC4 (0.43) KMOHDAC4HDAC2HDAC8LMNA
SCHEMBL26898819 0.90 PRKCI (0.43) KMOHDAC4HDAC2HDAC8HTR2C
SCHEMBL21332384 0.85 KMO (0.51) KMOHDAC4HDAC2HDAC8LMNA
SCHEMBL21665569 0.82 HDAC4 (0.50) KMOHDAC4HDAC2HDAC8LMNA
SCHEMBL22417171 0.82 HTR2C (0.62) HTR2CSLC18A3
SCHEMBL5667650 0.82 KMO (0.64) KMOHDAC4HDAC2HDAC8CYP11B2
SCHEMBL669730 0.82 KMO (0.64) KMOHDAC4HDAC2HDAC8CYP11B2
SCHEMBL6627916 0.81 KMO (0.49) KMOHDAC4HDAC2HDAC8LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024305-A1 METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS ALKAHEST, INC. 2024-01-25 US disclosed
US-RE45323-E1 Substituted piperidines as CCR3 antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024305-A1 METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS CCR3, CCR1, CCR4 KMO 3187/4885HDAC4 1223/4885HDAC2 1586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.